RecallHawk

PRISMASOL BGK2/0 (MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTAS...

VANTIVE US HLTHCARE

Summary

FDA approved PRISMASOL BGK2/0 (MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE) by VANTIVE US HLTHCARE. NDA (New Drug) approval (Labeling) on 2023-05-02. INJECTABLE, INJECTION.

Details

Source

Drug Approval

External ID

NDA021703-23

Action Date

2023-05-02

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

PRISMASOL BGK2/0 (generic: MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE), INJECTABLE, INJECTION. Application: NDA021703

Context & Analysis

VANTIVE US HLTHCARE has 3 FDA actions in our database.

Frequently Asked Questions

How often does VANTIVE US HLTHCARE have FDA actions?

VANTIVE US HLTHCARE has 3 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA021703-23" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions